Strong Q1 prompts an improved guidance
05/05/21 -"2021 started on a high as Novo reported robust growth, despite ‘tough comps’, i.e. forward buying-driven Q1 20. Moreover, as management expects this momentum to be maintained, the 2021 outlook has ..."
Pages
68
Language
English
Published on
05/05/21
You may also be interested by these reports :
27/07/26
The Q2 26 results were largely in line with the street’s expectations. Strong growth in oncology, respiratory, immunology and rare disease treatments ...
23/07/26
Despite FX headwinds, the Q2 results were ahead of the street’s expectations. The performance was driven by drugs across therapeutic areas, and the ...
22/07/26
Lonza published its 1H results, with a strong operating performance but a mixed revenue outcome. The group grew by +16% (CER) YoY, with strong FX ...
21/07/26
The Q2 sales growth was supported by a healthy showing across both segments. The management now expects full-year growth to be at the upper end of ...